Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (215)

31

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19

32

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19

33

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19

34

How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von van de Donk, N.

35

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

36

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

enthalten in: Blood | 2023

von Cohen, A. | Mateos, M. | Cohen, Y. | +21

CommentIn: Blood. 2023 Jan 19;141(3):211-212. - PMID 36656612

37

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

enthalten in: The New England journal of medicine | 2022

von Chari, A. | Minnema, M. | Berdeja, J. | +17

CommentIn: N Engl J Med. 2022 Dec 15;387(24):2287-2290. - PMID 36507665

38

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001) : a multicentre, multicohort, open-label, phase 1/2 trial

enthalten in: The Lancet. Haematology | 2022

von Lonial, S. | Popat, R. | Hulin, C. | +18

CommentIn: Lancet Haematol. 2022 Nov;9(11):e799-e801. - PMID 36209763

39

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma : A European Myeloma Network (EMN) Report Within the HARMONY Project

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von D'Agostino, M. | Cairns, D. | Lahuerta, J. | +28

ErratumIn: J Clin Oncol. 2022 Dec 1;40(34):4032. - PMID 36260864

40

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Hofste Op Bruinink, D. | Kuiper, R. | van Duin, M. | +16

CommentIn: J Clin Oncol. 2022 Sep 20;40(27):3099-3102. - PMID 35759726